CRISPR & CRISPR Associated Genes Market – By Type , By Application , By End User , By Geography – Global Opportunity Analysis & Industry Forecast, 2024-2030

CRISPR & CRISPR Associated Genes Market Overview

CRISPR & CRISPR Associated Genes market size is forecast to reach US$330.6 million by 2030, after growing at a CAGR of 9.6% during 2024-2030. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated genes (Cas) are potent gene-editing tools that enable accurate DNA alteration in living things. The Cas proteins in CRISPR systems are guided to particular DNA sequences by RNA molecules, allowing them to perform precise cuts or modifications. Genetics has been transformed by this technology, which has uses in biotechnology, agriculture and medicine. The rising investments in genomics research, rapid advancements in CRISPR technology, development of novel therapies and increasing research and development activities are the major drivers of the CRISPR & CRISPR Associated Genes market. CRISPR and CRISPR-associated proteins have introduced perfect precision in gene editing techniques that are affordable and easy to use. They are applicable in almost all sectors such as research, medicine, agriculture and industrial uses. The significant features of the CRISPR markets growth are; in consumers increasing resort to CRISPR in gene therapy for inherited diseases, improvement in the diagnosis capabilities based on CRISPR technology and finally, the increasing applications of CRISPR in agriculture for the production of disease resistant crops and animals. Innovations in CRISPR delivery systems such as advanced viral vectors and non-viral vector systems are also enhancing the rate of CRISPR market development while supporting regulatory frameworks are counter balancing the technology adoption in other fields.

Report Coverage

The report "CRISPR & CRISPR Associated Genes Market Report – Forecast (2024-2030)" by IndustryARC covers an in-depth analysis of the following segments of the CRISPR & CRISPR Associated Genes market.

COVID-19 / Ukraine Crisis - Impact Analysis:  

• The coronavirus outbreak set the stage for a global health crisis, which in turn showcased the versatility of CRISPR technologies reinforcing its potential market in healthcare systems for prevention diagnosis and treatment of diseases particularly infectious ones. During the pandemic, the rapid rate of infection led to the need for rapid testing as well. CRISPR was used to develop rapid diagnostic tests and also explore potential therapeutic treatments which positively benefitted the market
• The Russia-Ukraine conflict has had a mixed impact on the CRISPR and CRISPR-associated genes market, disrupting global supply chains for key research materials and reagents. Additionally, the war heightened interest in CRISPR for applications like crop resilience and biosecurity prompting renewed focus on agricultural and healthcare solutions.

Key Takeaways

Products are the Largest Segment

The products of CRISPR technology and its associated genes is becoming a strong leader in the industry and transforming many of the businesses including health care and agriculture. The rising need for precision medicine, genetic therapeutics, and diagnostics has also contributed to a rising trend in the CRISPR products. In August 2023, CrisprBits announced a collaboration with Molbio Diagnostics for the development of CRISPR-based Point-of-Care tests. This provides a crucial progression toward the enhancement of diagnostic testing that is accessible, affordable, and efficient at the point of care. These and other technologies are propelling the market, offering portable strategies for genetic assessment and pathology even within a matter of seconds. Expansion of CRISPR technology leads to expansion of the scope of application of CRISPR and CRISPR-associated genes which have established themselves as significant areas in biotechnology and the health sector promoting better efficiency in treatment and diagnosis of illnesses around the world.

Genome Engineering is the Largest Segment

Genome engineering is the largest segment in the CRISPR and CRISPR-associated genes market driven by its transformative potential in various industries including agriculture, healthcare, and biotechnology. This technique allows precise modification of DNA, offering advancements in disease treatment, crop improvement, and more. In May 2024, Bayer AG advanced two initiatives with external partners to bring forward genome editing in vegetables. Bayer and South Korean biotech company G+FLAS entered into an agreement to develop genome-edited tomato varieties enriched with vitamin D3 demonstrating the growing role of genome engineering in agricultural innovation. As the market continues to expand, genome engineering is expected to revolutionize food production, personalized medicine and genetic therapies attracting significant investments and fostering breakthroughs across multiple sectors.

North America Leads the Market

In the North America region, especially in the USA, a large share of the CRISPR and CRISPR-associated genes (Crispr-Cas) market is concentrated due to most of the CRISPR based research and applications owing to majority of the innovation and application of gene editing technologies. In the US, there are many agro-biotech companies and academic institutions engaged in gene editing rising technologies, which makes US trends dominate the practices in agriculture, medicine and biotechnology all over the globe. This leadership is even more pronounced in controversies such as the one on the risk posed by CRISPR technologies. According to the survey by the Pew Research Center, among US adults, it was evenly split with 30% saying the socially advanced use of genetic editing to ensure very low chances of serious ailments for a child being born is a good idea and 30% opted for it as a bad idea. This schism illustrates the divisive nature of the issue and the ongoing debates on the risks and advantages of CRISPR.

Increasing Research and Development Activities Fuels Growth 

The CRISPR and CRISPR-associated genes market has recently experienced significant developments in gene-editing technologies due to increased research and development(R&D) activities in this field. Because of the increasing need for accurate and fast genetic changes, investigation into the other possible applications is extending to medicine, agriculture and biotechnology. According to data shared by the Alliance for Regenerative Medicine at the 2024 Cell & Gene Meeting on the Mesa, investment in cell and gene therapies in the first half of 2024 reached $10.9 billion, surpassing 2019’s total of $9.8 billion. Such technological developments are improving the gene editing accuracy and lowering the costs which in turn allows the rapid development of CRISPR-based therapies and applications, thus further driving the growth of the market.

Off-target Effects to Hinder Growth

One of the primary challenges associated with CRISPR technology is the risk of off-target effects and unintended consequences. Off-target effects occur when the CRISPR-Cas9 system inadvertently cuts DNA at unintended sites in the genome. This can lead to unintended genetic mutations, which may have harmful consequences for the organism. Unintended consequences can arise from both on-target and off-target effects. For example, even if the CRISPR system accurately edits the intended gene, it may have unexpected downstream effects on other genes or cellular processes.

For more details on this report - Request for Sample

CRISPR & CRISPR Associated Genes Industry Outlook

Technology launches, acquisitions, and R&D activities are key strategies adopted by players in the CRISPR & CRISPR Associated Genes market. Global CRISPR & CRISPR Associated Genes top 10 companies include:

1. Bio-Rad Laboratories, Inc
2. Thermo Fisher Scientific, Inc
3. Merck KGaA
4. QIAGEN 
5. Cytiva
6. CRISPR Therapeutics AG
7. Editas Medicine
8. Caribou Biosciences, Inc
9. New England Biolabs
10. Origene Technologies, Inc

Scope of the Report: 

For more Lifesciences and Healthcare Market reports, please click here